Fosamax and Osteonecrosis of the Jaw: A Clinical Evidence Review

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Specialized Inquiry

The legacy of general health and science information has long served as a foundation for public understanding of medical conditions and therapeutic interventions. Within this broad context, the dissemination of knowledge about osteoporosis management and the use of bisphosphonates like Fosamax has been a routine part of clinical education. Patients and providers alike have relied on established guidelines to weigh benefits against potential adverse effects, with a focus on skeletal health outcomes. As the volume of clinical evidence has grown, attention has increasingly turned to rare but serious complications associated with long-term medication use. This shift in focus naturally extends from a general health perspective to a more specialized inquiry into specific exposure scenarios.

Bridging to Occupational Exposure Concerns

In the occupational setting, where workers may encounter pharmaceutical compounds during manufacturing, handling, or disposal, the question of risk takes on a distinct dimension. The transition from a patient-centered view of medication safety to an occupational exposure concern requires careful consideration of how clinical findings translate into workplace hazard assessments. While the original health information framework provided essential baseline knowledge, the pivot toward occupational contexts demands an evaluation of exposure pathways, duration, and intensity that differ markedly from therapeutic use. This bridge concept allows for a systematic examination of how clinical evidence on Fosamax and osteonecrosis of the jaw informs occupational health practices without presuming mechanistic links.

Fosamax: Mechanism and Approved Uses

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Osteonecrosis of the Jaw: Clinical Presentation and Diagnosis

A serious adverse effect associated with bisphosphonate therapy, including Fosamax, is osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation often involves pain, swelling, infection, and exposed bone that fails to heal within eight weeks after identification. Diagnosis is primarily clinical, based on visual inspection and history, with imaging such as panoramic radiographs or CT scans used to assess extent. The condition has been reported in patients taking bisphosphonates, including Fosamax and Fosamax Plus D (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways Linking Fosamax to ONJ

The mechanistic pathways linking Fosamax to ONJ are not fully elucidated but are believed to involve the drug's potent inhibition of osteoclast activity. Bisphosphonates accumulate in bone, particularly in areas of high turnover such as the jaw, and suppress bone remodeling. This suppression can impair the ability of the jawbone to repair microdamage and respond to local stressors like dental procedures or infection. Multiscale characterization of jawbone tismedical context has provided comprehensive information that can help understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). Additionally, bisphosphonates may have anti-angiogenic effects, reducing blood supply to the jawbone, and can alter immune responses, predisposing to infection and necrosis.

Risk Factors and Temporal Relationship

Risk factors for developing ONJ while on Fosamax include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The timeline between Fosamax exposure and documented health outcomes varies. The time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping Fosamax, but a subset experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a recognized risk, its incidence in the general osteoporosis population may be low, and other factors contribute significantly.

Safety Communication and Clinical Management

From a safety-communication perspective, the U.S. Food and Drug Administration has included warnings about ONJ in the prescribing information for Fosamax and Fosamax Plus D. These warnings advise healthcare professionals to perform a routine oral examination before initiating bisphosphonate therapy, especially in patients with risk factors. Patients should be instructed to maintain good oral hygiene and to report any oral symptoms such as pain, swelling, or non-healing sores. For those undergoing invasive dental procedures, a drug holiday may be considered to reduce risk, though the optimal duration of discontinuation is not established. For affected patients, causation-focused clinical interpretation requires careful assessment. While Fosamax is a known risk factor, ONJ can occur spontaneously and is often associated with local factors like dental procedures or infection. The temporal relationship—symptoms appearing days to months after starting the drug—supports a potential causal link, but the similar incidence in placebo groups in clinical trials indicates that other causes must be considered. In patients with multiple risk factors, such as cancer or concomitant corticosteroid use, the contribution of Fosamax may be more difficult to isolate. Management typically involves discontinuation of the bisphosphonate, conservative debridement, antibiotics, and oral rinses, with referral to an oral surgeon for advanced cases.

Summary of Evidence and Clinical Implications

In summary, the evidence supports a causal association between Fosamax and osteonecrosis of the jaw, particularly in the presence of additional risk factors. The risk appears to increase with longer exposure and is mitigated by dental preventive measures and possibly drug discontinuation before invasive procedures. Clinicians should weigh the benefits of Fosamax for fracture prevention against the low but serious risk of ONJ, especially in patients with pre-existing dental disease or those requiring dental surgery.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified medical contexts for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how does it work?

Fosamax (alendronate) is a bisphosphonate medication used to treat and prevent osteoporosis. It works by inhibiting bone resorption, which increases bone mass and reduces fracture risk. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)

What is osteonecrosis of the jaw (ONJ) and how is it diagnosed?

ONJ is a condition of exposed, non-healing bone in the jaw, often associated with dental procedures or infection. Diagnosis is clinical, based on visual inspection and history, with imaging used to assess extent. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid conditions like periodontal disease. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1)

How long does it take for ONJ symptoms to appear after starting Fosamax?

The time to onset of symptoms can range from one day to several months after starting the drug. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)

Does submitting information create an medical context-client relationship?

No. Submission requests an initial records screening only and does not create an medical context-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.